🇺🇸 Pegylated G-CSF in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 2
Most-reported reactions
- Covid-19 — 1 report (50%)
- Plasma Cell Myeloma — 1 report (50%)
Other Oncology approved in United States
Frequently asked questions
Is Pegylated G-CSF approved in United States?
Pegylated G-CSF does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pegylated G-CSF in United States?
Australasian Gastro-Intestinal Trials Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.